GlassScriptPhysician profile
William Aaron Retterbush
NPI 1053934844
$9,896.37
in general payments reported to CMS, 2019-2025
29 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,112 · 2022: $1,770 · 2023: $1,806 · 2024: $2,615 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,758 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,757.77 |
| Education | $256.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,947.73 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $851.19 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $836.77 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $707.94 | 2021-2025 | Bimzelx |
| Amgen INC. | $663.36 | 2021-2025 | Otezla, Enbrel, Otezla |
| Dermavant Sciences, INC. | $592.32 | 2022-2024 | Vtama |
| Leo Pharma INC. | $477.72 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $391.67 | 2021-2025 | |
| Janssen Biotech, INC. | $381.92 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $377.73 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $356.79 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $349.35 | 2021-2025 | |
| Pfizer INC. | $342.52 | 2023-2025 | |
| Epi Health, LLC | $301.91 | 2021-2022 | |
| Incyte Corporation | $300.61 | 2023-2025 | Opzelura |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $245.03 | 2021-2025 | Nemluvio |
| Botanix Sb INC | $113.52 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $109.34 | 2023 | |
| Arcutis Biotherapeutics, INC. | $92.35 | 2023-2025 | Zoryve |
| Almirall LLC | $92.15 | 2021-2022 | |
| Organon LLC | $84.45 | 2025 | Vtama, Nexplanon |
| Sanofi-Aventis U.S. LLC | $67.70 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.93 | 2021-2024 | Jublia |
| Biofrontera INC. | $44.64 | 2021 | |
| Vyne Pharmaceuticals INC. | $29.35 | 2021 | |
| Convatec INC. | $24.72 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.42 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.76 | 2022 | |
| Stemline Therapeutics INC. | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Retterbush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.